1. Home
  2. FLYW vs HROW Comparison

FLYW vs HROW Comparison

Compare FLYW & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flywire Corporation Voting

FLYW

Flywire Corporation Voting

HOLD

Current Price

$16.26

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

HROW

Harrow Inc.

HOLD

Current Price

$39.03

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLYW
HROW
Founded
2009
1998
Country
United States
United States
Employees
N/A
373
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
FLYW
HROW
Price
$16.26
$39.03
Analyst Decision
Buy
Strong Buy
Analyst Count
14
8
Target Price
$16.21
$69.86
AVG Volume (30 Days)
1.9M
578.3K
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
450.00
N/A
EPS
0.10
N/A
Revenue
$623,025,000.00
N/A
Revenue This Year
$19.68
$31.62
Revenue Next Year
$15.25
$50.77
P/E Ratio
$165.60
N/A
Revenue Growth
26.59
N/A
52 Week Low
$10.11
$28.54
52 Week High
$18.98
$54.98

Technical Indicators

Market Signals
Indicator
FLYW
HROW
Relative Strength Index (RSI) 46.26 42.68
Support Level $13.27 $37.81
Resistance Level $17.03 $41.94
Average True Range (ATR) 0.64 2.29
MACD -0.27 -0.88
Stochastic Oscillator 27.98 21.60

Price Performance

Historical Comparison
FLYW
HROW

About FLYW Flywire Corporation Voting

Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements, namely a payments platform, a proprietary payment network, and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Share on Social Networks: